Company profile
Kowa Company, Ltd.
Privately held: no public share price
Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Pemafibrate(Parmodia) | Phase 3 | PPAR-alphaSmall molecule | Chronic Kidney DiseaseAtherosclerotic Cardiovascular Disease |
Tofogliflozin(Apleway / Deberza) | Phase 2 | SGLT2Small molecule | Type 2 Diabetes |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.